News Breaks |
|
|
| January 16, 2013 |
| 09:22 EDT |  | STJ | St. Jude Medical warning letter not clearing event, says Citigroup
Citigroup believes the next FDA action regarding St. Jude Medical's Sylmar is likely to be a threat of injunction that normally leads to a consent decree. Further, Citi believes the FDA will ultimately have to make a determination on the safety of Durata, with the firm still believing a recall is likely. Citi says the FDA's Sylmar Warning Letter is not a clearing event, but the next step in a process that looks ominous for St. Jude. The firm keeps a Sell rating on the stock with a $32 price target. |
|
|
News For STJ From The Last 14 Days Check below for free stories on STJ the last two weeks. |
|
|
| May 16, 2013 |
| 08:05 EDT |  | STJ | St. Jude Medical's 3-D vessel reconstruction system approved in Europe
St. Jude Medical announced CE Mark approval of its Ilumien Optis PCI Optimization System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease. St. Jude Medical is the only company to provide these tools together in an integrated platform. |
|
| May 14, 2013 |
| 08:09 EDT | | STJ | St. Jude Medical announces first patient enrolled in EnligHTN III study
 Subscribe for More Information |
|
| May 9, 2013 |
| 14:01 EDT | | STJ | St. Jude says analysis demonstrates safety, reliability of Optim-insulated leads
Subscribe for More Information |
|
| 09:27 EDT |  | STJ | Leerink's medical devices analyst holds a conference call
Subscribe for More Information |
|
| May 8, 2013 |
| 08:09 EDT | | STJ | St. Jude Medical announces CE Mark approval of ICDs, CRT-Ds
Subscribe for More Information |
|
|
|
|
|
